Sign In
Buy DCPH
$25.59
+0 (+0%)
At Close: Sep 09, 2024
3 Biotech Stocks That Could Double Soon
06:44am, Wednesday, 21'st Jul 2021
Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.
Deciphera (DCPH) Begins Dosing in Study on Cancer Candidate
11:17am, Thursday, 01'st Jul 2021
Deciphera (DCPH) doses the first patient in a phase I study evaluating its ULK kinase inhibitor, DCC-3116, for treating advanced/metastatic tumors driven by mutations in RAS/RAF genes.
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 10.8% Since Last Earnings Report?
12:48pm, Thursday, 03'rd Jun 2021
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?
Near a 2-Year Low, Is Deciphera Pharmaceuticals a Buy?
06:23am, Thursday, 13'th May 2021
The company isn't earning a profit yet, but there are solid reasons why it's worth considering, particularly at its current share price.
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q1 2021 Results - Earnings Call Transcript
12:25am, Monday, 10'th May 2021
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q1 2021 Results - Earnings Call Transcript
Deciphera (DCPH) Q1 Loss Narrower Than Expected, Revenues Beat
01:09pm, Wednesday, 05'th May 2021
Deciphera (DCPH) posts a narrower loss in the first quarter while sales beat on the encouraging uptake of Qinlock.
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results
04:22pm, Tuesday, 04'th May 2021
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2021, and provided a corporate update. “We are
BlackBerry, Lam Research, Shopify, Square, Zoom and More Wednesday Afternoon Analyst Calls
11:50am, Wednesday, 31'st Mar 2021
With the trading day about halfway over, the broad markets largely were pushing higher, except for the Dow Jones industrial average.
Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
07:00am, Tuesday, 02'nd Mar 2021
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Ba
Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference
07:00am, Thursday, 18'th Feb 2021
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the SV
Deciphera's Ripretinib In 2nd Line GIST: An Assessment
01:53am, Thursday, 18'th Feb 2021
Deciphera's Ripretinib In 2nd Line GIST: An Assessment
Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss
10:56am, Wednesday, 10'th Feb 2021
Deciphera Pharmaceuticals (DCPH) reports narrower-than-expected loss. Nonetheless, sales marginally surpass estimates for the fourth quarter of 2020.
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q4 2020 Results - Earnings Call Transcript
10:20pm, Tuesday, 09'th Feb 2021
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q4 2020 Results - Earnings Call Transcript
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Tuesday, 09'th Feb 2021
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 5.17% and 4.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for
Recap: Deciphera Pharmaceuticals Q4 Earnings
05:31pm, Tuesday, 09'th Feb 2021
Shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) were unchanged in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 16.03% year over year to ($
